Tipharco Pharmaceutical Joint Stock Company (DTG) would like to provide an explanation to the Commission, the Exchange, and the Company's shareholders regarding the changes in revenue and profit after tax presented in the financial statements for third-quarter of 2026 compared with the same period in 2025, as follows:
Source: Third-quarter 2026 financial statements
Profit after tax for the third quarter of 2026 increased compared to the same period of the previous year, primarily due to the Company's continued implementation of measures to improve the efficiency of its business and production operations. In particular, the procurement of raw materials was closely managed, helping to stabilize input material prices and thereby maintain effective control over production costs.
At the same time, the Company adjusted its production and business plans in line with market demand, contributing to better control over production costs, an improvement in the gross profit margin, and enhanced operating efficiency during the period.
In addition, the Company continued to exercise strict control over its capital resources and debt structure, resulting in lower financial expenses compared to the same period of the previous year and thereby contributing to improved business performance.
The above provides the Company's explanation of the changes in its business performance for the third quarter of 2026 compared to the same period of the previous year. The Company respectfully informs its valued shareholders, investors, and other relevant stakeholders.
Thank you for your attention.
Attachments: